Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02
FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study’s primary objectives
Plasma concentrations within the potential therapeutic dose range were consistent with efficacious exposure levels established in nonclinical disease models and support once-daily oral dosing
Related news for (FRTX)
- Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market
- Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution
- Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
- Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
- Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th